Rein Therapeutics (RNTX) EBIAT (2016 - 2025)
Rein Therapeutics filings provide 10 years of EBIAT readings, the most recent being -$32.0 million for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 22.0% year-over-year to -$32.0 million, compared with a TTM value of -$49.9 million through Dec 2025, up 20.69%, and an annual FY2025 reading of -$49.9 million, up 20.69% over the prior year.
- EBIAT hit -$32.0 million in Q4 2025 for Rein Therapeutics, down from -$5.6 million in the prior quarter.
- The five-year high for EBIAT was -$1.8 million in Q2 2023, with the low at -$41.0 million in Q4 2024.
- Median EBIAT over the past 5 years was -$6.8 million (2021), compared with a mean of -$9.1 million.
- The sharpest move saw EBIAT skyrocketed 77.64% in 2023, then tumbled 458.4% in 2024.
- Year by year, EBIAT stood at -$6.8 million in 2021, then skyrocketed by 33.12% to -$4.5 million in 2022, then crashed by 61.4% to -$7.3 million in 2023, then plummeted by 458.4% to -$41.0 million in 2024, then increased by 22.0% to -$32.0 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$32.0 million, -$5.6 million, and -$6.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.